MIST - Milestone Pharmaceuticals GAAP EPS of -$0.31 revenue of $3.5M

2023-03-29 16:59:22 ET

• Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q4 GAAP EPS of -$0.31.
• Revenue of $3.5M.
• As of December 31, 2022, Milestone had cash, cash equivalents, and short-term investments of $64.6 million, compared to $114.1 million as of December 31, 2021, and 34.3 million
• General and administrative expense for the fourth quarter of 2022 was $4.1 million, compared with $3.8 million for the prior year period. For the full year ended December 31, 2022
• For the fourth quarter of 2022, operating loss was $13.2 million, compared to $16.9 million for the prior year period. For the full year ended December 31, 2022, Milestone's operating loss was $58.4 million, compared to $42.9 million for the prior year.

For further details see: